We are monitoring the impact of COVID-19 & Recession alarm on Latin America Antibodies Market Get in touch with us for detailed analysis Know More
Share on

Latin America Antibodies Market Research Report – Segmented By Product Type, Indication, End User, Application & By Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact and Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1116
Pages: 145

Latin America Antibodies Market Size (2022 to 2027)

The Latin American antibodies market size is estimated to be worth USD 15.29 billion by 2027 from USD 10.21 billion in 2022, growing at a CAGR of 8.41% CAGR during the forecast period. The market growth is attributed to rate highest adoption rate in price-sensitive markets and drug research.

An increase in the R&D activities, particularly in the life sciences industry, coupled with increasing collaborations between industry and academia, are key factors driving the Latin America antibodies market. The R&D sector has traditionally remained capital intensive due to long development periods and approval cycles. Investment in R&D occupies a privileged place in global spending. Governments recognize R&D as a crucial investment for the advancement of a nation, international competitiveness, and the public interest. For this reason, R&D spending and funding have grown steadily over the years. Currently, the growing demand for effective therapeutic drugs with fewer side effects has led to an increased focus on the R&D of biopharmaceuticals. An increase in research activity and availability of funds are expected to drive the overall purchase and consumption of antibodies, which in turn accelerates the growth rate of the Latin American antibodies market.

Additionally, the goal behind the production of personalized antibodies is to acquire an antibody that will work well in a particular qualitative or quantitative immune detection method. In addition, biopharmaceutical companies have almost doubled their R&D investments in personalized medicine over the past five years, and it is expected to increase by 33% over the next five years.

The demand for protein therapies, including hormones, vaccines, monoclonal antibodies, blood factors, and therapeutic enzymes, has increased recently. New protein therapies, such as bispecific antibodies and antibodies conjugated to small molecules, are under development. Protein therapy is widely recognized for its potential use in treating various types of diseases, and its demand has increased dramatically in recent years due to the increasing prevalence of chronic diseases.

Strict government regulations and government laws take longer to get approval for an antibiotic to enter the market; this has been one of the main causes which negatively affect the growth of the Latin American antibodies market. The quality of bespoke antibodies (to ensure reproducibility of results) is also a concern in this market, which is expected to hold back the market's growth rate.

Impact of COVID-19 on the Latin American antibodies market:

At the forefront of the COVID-19 epidemic, many researchers worldwide are involved in viral research into SARS-CoV-2, the virus that causes COVID-19. For both vaccines and therapies, the antibodies produced are tested for their functional effectiveness in neutralizing the target virus. Most of the service providers have prioritized actions to support the critical work of customers involved in COVID-19, such as offering a range of high-quality COVID-19 related research tools, reallocating R&D resources to develop products critical for SARS-Cov-2, drive supply chain and manufacturing flexibility to support the increased demand for existing products used for SARS-CoV-2 / COVID-19 research, and initiate discussions and collaborations across the region focused on SARS-CoV-2 diagnosis, drug and vaccine development.

This research report on the Latin American Antibodies market has been segmented and sub-segmented into the following categories:

By Product Type:

  • Monoclonal Antibodies
    • Murine
    • Chimeric
    • Humanized
    • Human
  • Polyclonal Antibodies
    • Type I
    • Type II
    • Type III
    • Type IV
    • Type V
    • Type VI
    • Type VII
    • Type VIII
  • Anti-body drug complexes
    • Immunogen Technology
    • Seattle Genetics Technology
    • Immunomedics Technology

By Indication:

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • CNS Disorders
  • Others (Inflammatory, Microbial Diseases, & Other)

By End User:

  • Hospitals/Clinics
  • Research institute
  • Diagnostics laboratories

By Application:

  • Medical
  • Experimental
  • Western blot
  • ELISA
  • Radioimmune Assays
  • Immunofluorescence
  • Others (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, the Brazilian antibodies market is expected to represent the largest share in the Latin American market during the forecast period. The growing incidence of cancer, public funding of medical research in the region, the need for quality cancer treatment, and regulatory approvals and authorization of antibodies used in Latin America are key factors in the market growth in this region.

The Mexican antibodies market is predicted to be another lucrative regional market in Latin America from 2022 to 2027.

The Argentina antibodies market is expected to register healthy CAGR during the forecast period. The presence of developed infrastructure, availability of budgets, increase in R&D spending for drug discovery and development services drive the market growth in this region.

KEY MARKET PLAYERS:

Some noteworthy companies operating in the Latin America Antibodies Market profiled in this report are Abbott Diagnostics, Novartis AG, Pfizer Inc, ThermoFisher Scientific Inc, Eli Lilly, and company, A.G. Scientific, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, and AbbVie Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies     

                                                5.1.1.1 Murine

                                                5.1.1.2 Chimeric

                                                5.1.1.3 Humanized

                                                5.1.1.4 Human 

                                5.1.2 Polyclonal Antibodies         

                                                5.1.2.1 Type I

                                                5.1.2.2 Type II

                                                5.1.2.3 Type III

                                                5.1.2.4 Type IV

                                                5.1.2.5 Type V

                                                5.1.2.6 Type VI

                                                5.1.2.7 Type VII

                                                5.1.2.8 Type VIII

                                5.1.3 Antibody-Drug Complexes

                                                5.1.3.1 Immunogen Technology

                                                5.1.3.2 Seattle Genetics Technology

                                                5.1.3.3 Immunomedics Technology

                5.2 By Indication                              

                                5.2.1 Cancer      

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Latin America                            

                                6.1.1 Introduction           

                                6.1.2 Brazil         

                                6.1.3 Argentina

                                6.1.4 Mexico     

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Antibodies Development                         

                                7.5.1 Targeted Therapies             

                7.6 Promising Antibodies in Pipeline                       

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Antibodies                            

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Abbott Diagnostics (US)                        

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 A.G. Scientific, Inc. (U.S.)                      

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 AbbVie Inc. (U.S.)                  

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Latin America Antibodies Market, By Product type, From 2022 - 2027 (USD Million)
  2. Latin America Monoclonal Antibodies Market, By Region, From 2022 - 2027 (USD Million)
  3. Latin America Polyclonal Antibodies Market, By Region, From 2022 - 2027 (USD Million)
  4. Latin America Antibody-Drug complexes Market, By Region, From 2022 - 2027 (USD Million)
  5. Latin America Antibodies Market, By Indication, From 2022 - 2027 (USD Million)
  6. Latin America Cancer Market, By Region, From 2022 - 2027 (USD Million)
  7. Latin America Auto immune diseases Market, By Region, From 2022 - 2027 (USD Million)
  8. Latin America infectious diseases Market, By Region, From 2022 - 2027 (USD Million)
  9. Latin America Cardiovascular diseases Market, By Region, From 2022 - 2027 (USD Million)
  10. Latin America CNS disorders Market, By Region, From 2022 - 2027 (USD Million)
  11. Latin America Antibodies Market, By End users, From 2022 - 2027 (USD Million)
  12. Latin America Hospitals Market, By Region, From 2022 - 2027 (USD Million)
  13. Latin America Research institute Market, By Region, From 2022 - 2027 (USD Million)
  14. Latin America Diagnostics laboratories Market, By Region, From 2022 - 2027 (USD Million)
  15. Latin America Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  16. Latin America Medical Market, By Region, From 2022 - 2027 (USD Million)
  17. Latin America Experimental Market, By Region, From 2022 - 2027 (USD Million)
  18. Brazil Antibodies Market, By Product type, From 2022 - 2027 (USD Million)
  19. Brazil Antibodies Market, By Indication, From 2022 - 2027 (USD Million)
  20. Brazil Antibodies Market, By End users, From 2022 - 2027 (USD Million)
  21. Brazil Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  22. Rest of Latin America Antibodies Market, By Product type, From 2022 - 2027 (USD Million)
  23. Rest of Latin America Antibodies Market, By Indication, From 2022 - 2027 (USD Million)
  24. Rest of Latin America Antibodies Market, By End users, From 2022 - 2027 (USD Million)
  25. Rest of Latin America Antibodies Market, By Application, From 2022 - 2027 (USD Million)
  26. Latin America Antibodies Market, By Monoclonal Antibodies, From 2022 - 2027 (USD Million)
  27. Latin America Murine Market, By Region, From 2022 - 2027 (USD Million)
  28. Latin America Chimeric Market, By Region, From 2022 - 2027 (USD Million)
  29. Latin America Humanized Market, By Region, From 2022 - 2027 (USD Million)
  30. Latin America Human Market, By Region, From 2022 - 2027 (USD Million)
  31. Brazil Antibodies Market, By Monoclonal Antibodies, From 2022 - 2027 (USD Million)
  32. Rest of Latin America Antibodies Market, By Monoclonal Antibodies, From 2022 - 2027 (USD Million)
  33. Latin America Antibodies Market, By Polyclonal Antibodies, From 2022 - 2027 (USD Million)
  34. Latin America Type I Market, By Region, From 2022 - 2027 (USD Million)
  35. Latin America Type II Market, By Region, From 2022 - 2027 (USD Million)
  36. Latin America Type III Market, By Region, From 2022 - 2027 (USD Million)
  37. Latin America Type IV Market, By Region, From 2022 - 2027 (USD Million)
  38. Latin America Type V Market, By Region, From 2022 - 2027 (USD Million)
  39. Latin America Type VI Market, By Region, From 2022 - 2027 (USD Million)
  40. Latin America Type VII Market, By Region, From 2022 - 2027 (USD Million)
  41. Latin America Type VIII Market, By Region, From 2022 - 2027 (USD Million)
  42. Brazil Antibodies Market, By Polyclonal Antibodies, From 2022 - 2027 (USD Million)
  43. Rest of Latin America Antibodies Market, By Polyclonal Antibodies, From 2022 - 2027 (USD Million)
  44. Latin America Antibodies Market, By Antibody-Drug Complexes, From 2022 - 2027 (USD Million)
  45. Latin America Immunogen Technology Market, By Region, From 2022 - 2027 (USD Million)
  46. Latin America Seattle Genetics Technology Market, By Region, From 2022 - 2027 (USD Million)
  47. Latin America Immunomedics technology Market, By Region, From 2022 - 2027 (USD Million)
  48. Brazil Antibodies Market, By Antibody-Drug Complexes, From 2022 - 2027 (USD Million)
  49. Rest of Latin America Antibodies Market, By Antibody-Drug Complexes, From 2022 - 2027 (USD Million)
  50. Latin America Antibodies Market, By Experimental, From 2022 - 2027 (USD Million)
  51. Latin America Western Blot Market, By Region, From 2022 - 2027 (USD Million)
  52. Latin America ELISA Market, By Region, From 2022 - 2027 (USD Million)
  53. Latin America Radioimmune Assays Market, By Region, From 2022 - 2027 (USD Million)
  54. Latin America immunofluorescence Market, By Region, From 2022 - 2027 (USD Million)
  55. Brazil Antibodies Market, By Experimental, From 2022 - 2027 (USD Million)
  56. Rest of Latin America Antibodies Market, By Experimental, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample